1. Generics Bulletin
  2. >>Business

Supplier Shortages To Benefit Amphastar For Many Quarters To Come

Amphastar Is The Only US Firm Supplying Dextrose, Sodium Bicarbonate And Pre-Filled Epinephrine Syringes

 
• By Chloe Kent

Amphastar management has assured stakeholders that it will continue to benefit from competitor shortages for the foreseeable future, with chief financial officer Bill Peters noting that the firm has been plugging gaps in the market throughout his near-decade at the company.

Woman staring at empty shelves with out of stock sign
• Source: Shutterstock

Following a successful third quarter driven by glucagon uptake and competitor shortages, Amphastar Pharmaceuticals, Inc. management expressed both on its results call and at the 2023 Jefferies Healthcare Conference – held in London in November – that capitalizing on said shortages will remain part of the company’s business strategy for the foreseeable future.

Amphastar manufactures multiple products that are currently in shortage and has found fresh opportunities following the tornado damage at a key Pfizer injectables plant. (Also see "Pfizer Rallies To Fix Tornado Damage At Key Injectables Plant" - Generics Bulletin, 24 July, 2023

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By Dave Wallace

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.